NewCardio

NewCardio EBIT

The EBIT of NewCardio (NWCI) as of Oct 6, 2026 is -9.46 M USD.

EBIT

-9.46 MUSD

Last updated:

In 2026, NewCardio's EBIT was -9.46 M USD, a % increase from the - USD EBIT recorded in the previous year.

The NewCardio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2006
-376,000.00 USD
Jan 1, 2007
-2.10 M USD
Jan 1, 2008
-7.83 M USD
Jan 1, 2009
-10.01 M USD
Jan 1, 2010
-9.46 M USD
Jan 1, 2011 (e)
0.00 USD
Jan 1, 2012 (e)
0.00 USD
The NewCardio EBIT history
YEAREBITYoY
est0.00USD—
est0.00USD-100.00%
-9.46 MUSD-5.52%
-10.01 MUSD+27.88%
-7.83 MUSD+272.80%
-2.10 MUSD+458.56%
-376,000.00USD—
Access this data via the Eulerpool API

NewCardio Revenue

NewCardio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
0.00 USD
-376,000.00 USD
-378,000.00 USD
Jan 1, 2007
0.00 USD
-2.10 M USD
-3.19 M USD
Jan 1, 2008
0.00 USD
-7.83 M USD
-14.18 M USD
Jan 1, 2009
0.00 USD
-10.01 M USD
-9.59 M USD
Jan 1, 2010
257,399.00 USD
-9.46 M USD
-11.50 M USD
Jan 1, 2011 (e)
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2012 (e)
0.00 USD
0.00 USD
0.00 USD

NewCardio Margins

NewCardio stock margins

The NewCardio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NewCardio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NewCardio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
40.83 %
- %
- %
Jan 1, 2007
40.83 %
- %
- %
Jan 1, 2008
40.83 %
- %
- %
Jan 1, 2009
40.83 %
- %
- %
Jan 1, 2010
40.83 %
-3,674.93 %
-4,466.32 %
Jan 1, 2011 (e)
40.83 %
0.00 %
0.00 %
Jan 1, 2012 (e)
40.83 %
0.00 %
0.00 %

NewCardio Stock analysis

What does NewCardio do? NewCardio Inc is a leading company in the medical technology industry that specializes in the development and marketing of innovative solutions to improve cardiovascular diagnostics and patient monitoring systems. The company's history began in 2003 when a group of experts and experienced scientists from the medical technology industry decided to develop a new technology together to monitor the electrical activity of the heart. This technology was intended to allow for more accurate diagnosis of cardiovascular diseases and thus provide better treatment options. Over the following years, several patents were filed and the technology was further developed. In 2008, NewCardio Inc was finally founded with the goal of launching the portfolio. NewCardio Inc's business model is based on the development and marketing of CardioBip systems, the company's core technology. The CardioBip system is a non-invasive, wireless, ECG-supported monitoring platform to improve cardiovascular diagnostics. The system is based on the analysis of real-time ECG data transmitted via Bluetooth to a smartphone or other mobile device. The company operates several business areas, including medical technology, clinical trials, and KinetoGen. The medical technology division focuses on the development and marketing of products that improve cardiovascular diagnostics. The CardioBip system is the core product of the medical technology division, but other products such as CardioVolt, CardioCore, and CardioKit are also available. These products offer a variety of features that improve cardiovascular diagnostics and offer numerous applications. The clinical trials division provides support for conducting clinical trials. The company offers digital, wireless ECG monitoring and efficient data analysis to ensure better clinical research. NewCardio's products enable more efficient conduct of clinical trials, saving time and costs. The KinetoGen division is a joint venture with Kineticor, a company that develops technologies for monitoring patients after surgical procedures. The joint venture specializes in the development of products that improve the prognosis and management of postoperative cardiovascular disorders. NewCardio Inc is committed to providing innovative solutions and technologies to improve cardiovascular diagnostics. NewCardio's products are unique in the market as they represent a wireless, non-invasive solution for monitoring cardiovascular diseases. Overall, NewCardio Inc is a unique company whose products and technologies improve cardiovascular diagnostics and optimize patient care. The company is focused on growth and continues to work on developing new innovative solutions to expand its portfolio. NewCardio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing NewCardio's EBIT

NewCardio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of NewCardio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

NewCardio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in NewCardio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about NewCardio stock

EBIT of NewCardio is -9.46 M USD in 2026.

On Eulerpool you can find the complete historical development of EBIT NewCardio since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's NewCardio historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — NewCardio

All Key Metrics — NewCardio